NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $64.65 -4.39 (-6.36 %) (As of 03/25/2019 06:00 AM ET)Previous Close$64.65Today's Range$64.56 - $68.8852-Week Range$37.44 - $90.98Volume630,416 shsAverage Volume816,521 shsMarket Capitalization$3.32 billionP/E Ratio-8.75Dividend YieldN/ABeta2.21 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA. Receive RARE News and Ratings via Email Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE Previous Symbol CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.90Price-To-Earnings Trailing P/E Ratio-8.75 Forward P/E Ratio-9.52 P/E GrowthN/A Sales & Book Value Annual Sales$51.49 million Price / Sales64.39 Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book5.37Profitability EPS (Most Recent Fiscal Year)($7.39) Net Income$-197,610,000.00 Net Margins-383.75% Return on Equity-35.26% Return on Assets-30.62%Miscellaneous EmployeesN/A Outstanding Shares51,280,000Market Cap$3.32 billion Next Earnings Date5/6/2019 (Estimated) OptionableOptionable Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released its quarterly earnings results on Tuesday, February, 19th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.74) by $0.01. The biopharmaceutical company earned $16.26 million during the quarter, compared to analysts' expectations of $13.30 million. Ultragenyx Pharmaceutical had a negative return on equity of 35.26% and a negative net margin of 383.75%. View Ultragenyx Pharmaceutical's Earnings History. When is Ultragenyx Pharmaceutical's next earnings date? Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Ultragenyx Pharmaceutical. What price target have analysts set for RARE? 17 Wall Street analysts have issued 12 month price targets for Ultragenyx Pharmaceutical's stock. Their forecasts range from $59.00 to $95.00. On average, they anticipate Ultragenyx Pharmaceutical's share price to reach $77.7647 in the next year. This suggests a possible upside of 20.3% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical. What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical. What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock? Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock: 1. According to Zacks Investment Research, "Ultragenyx is encouraged by the growing demand for Crysvita from both children and adults with X-linked hypophosphatemia (XLH) inthe United States. During the third quarter, Mepsevii received European approval under exceptional circumstances for the treatment of non-neurological manifestations of MPS VII. In 2019, the company expects to file for potential approval of its third therapy, UX007 in fatty acid oxidation disorders. Ultragenyx continues to advance its two gene therapy clinical programs —DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency—with additional data expected around the end of 2018 and in 2019 respectively. However, the company plans to discontinue the study, evaluating UX007 in patients with Glut1 DS, as it did not achieve its primary endpoint, which does not bode well for the company. Loss estimates have remained stable ahead of the Q4 earnings release." (1/17/2019) 2. JPMorgan Chase & Co. analysts commented, "Ahead of the pending Phase 3 results for UX007 (trihep) in Glut1 DS expected sometime this quarter, we sifted through early data and market sizing assumptions to frame expectations and potential upside/downside on the event. Bottom line, while directly comparable data are limited to say the least (most similar pilot study only had an N of 6 and Phase 2 trials evaluated different endpoints), we believe a positive read- out is the most likely outcome given proof of concept data combined with seemingly reasonable powering assumptions. Between the recent pullback in shares (15% since 9/25) and our sense that this opportunity is not well understood by the market, we see risk/reward slightly skewed to the upside. Maintain OW." (10/7/2018) Has Ultragenyx Pharmaceutical been receiving favorable news coverage? Press coverage about RARE stock has trended neutral recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the next few days. Who are some of Ultragenyx Pharmaceutical's key competitors? Some companies that are related to Ultragenyx Pharmaceutical include GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT) and Amarin (AMRN). What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Celgene (CELG), Netflix (NFLX), GALAPAGOS NV/S (GLPG), Intercept Pharmaceuticals (ICPT), Gilead Sciences (GILD), TG Therapeutics (TGTX), Mallinckrodt (MNK), GW Pharmaceuticals PLC- (GWPH), Portola Pharmaceuticals (PTLA) and Vertex Pharmaceuticals (VRTX). Who are Ultragenyx Pharmaceutical's key executives? Ultragenyx Pharmaceutical's management team includes the folowing people: Emil D. Kakkis, President, Chief Executive Officer & DirectorWladimir Hogenhuis, Chief Operating OfficerShalini Sharp, Chief Financial Officer & Executive Vice PresidentDennis Karl Huang, Chief Technical Operations Officer & Senior VPEric Crombez, Chief Medical Officer Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.85%), FMR LLC (5.75%), First Trust Advisors LP (2.91%), Northern Trust Corp (1.15%), Geode Capital Management LLC (1.12%) and Geode Capital Management LLC (1.11%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical. Which major investors are selling Ultragenyx Pharmaceutical stock? RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, WS Management Lllp, Fosun International Ltd, MetLife Investment Advisors LLC, Bellevue Group AG, New York State Common Retirement Fund, California Public Employees Retirement System and Strs Ohio. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical. Which major investors are buying Ultragenyx Pharmaceutical stock? RARE stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, D. E. Shaw & Co. Inc., First Trust Advisors LP, BlackRock Inc., Hudson Bay Capital Management LP, Macquarie Group Ltd., Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Ultragenyx Pharmaceutical. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $64.65. How big of a company is Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical has a market capitalization of $3.32 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-197,610,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis. What is Ultragenyx Pharmaceutical's official website? The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at (415) 483-8800 or via email at [email protected] MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 623 (Vote Outperform)Underperform Votes: 283 (Vote Underperform)Total Votes: 906MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?